5053-14-5

Basic information

• Product Name: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
• Synonyms: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one
• CAS NO: 5053-14-5
• Molecular Formula: C₁₄H₁₈N₂O₂
• Molecular Weight: 246.31
• Mol File: 5053-14-5.mol

Chemical Properties

• Boiling Point: 457.1°Cat760mmHg
• Flash Point: 230.2°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 1.54E-08mmHg at 25°C
• Refractive Index: 1.6
• CAS DataBase Reference: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one(5053-14-5)
• EPA Substance Registry System: 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one(5053-14-5)

Safety Data

• Hazardous Substances Data: 5053-14-5(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one is used as a potential pharmaceutical agent for its diverse biological activities. 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one's unique structure and the presence of heteroatoms contribute to its potential applications in the development of new drugs.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one is used as an antimicrobial agent to combat various types of bacteria and other microorganisms. Its unique structure and functional groups may contribute to its ability to disrupt microbial cell walls or interfere with essential cellular processes, thereby inhibiting microbial growth.
Used in Anticancer Applications:
8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one is used as an anticancer agent, where its unique molecular structure may allow it to target specific cancer cells or pathways, leading to the inhibition of tumor growth and progression. 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one's potential to modulate various signaling pathways involved in cancer development and metastasis makes it a promising candidate for further research and development in oncology.
Used in Central Nervous System Modulation:
In the context of central nervous system (CNS) research, 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one is used as a modulating agent to explore its potential effects on neurological functions and disorders. 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one's unique structure and the presence of heteroatoms may enable it to interact with specific receptors or neurotransmitter systems, offering new avenues for the treatment of CNS-related conditions.
Used in Drug Delivery Systems:
To enhance the bioavailability, delivery, and therapeutic outcomes of 8-Benzyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one, various drug delivery systems are being developed. These systems may include organic and metallic nanoparticles, liposomes, or other carriers designed to improve the compound's solubility, stability, and targeted delivery to specific tissues or cells, thereby optimizing its pharmacological effects and minimizing potential side effects.

InChI:InChI=1/C14H18N2O2/c17-13-15-11-14(18-13)6-8-16(9-7-14)10-12-4-2-1-3-5-12/h1-5H,6-11H2,(H,15,17)

Upstream product

• 156215-49-5 1-benzyl-4-(trimethylsilyloxy)piperidine-4-carbonitrile 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 77211-73-5 2-(1-benzyl-4-hydroxypiperidin-4-yl)acetyl hydrazine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 105-58-8 Diethyl carbonate 
• 67281-07-6 ethyl 2-(1-benzyl-4-hydroxypiperidin-4-yl)acetate 
• 177948-01-5 [[4-hydroxy-1-(phenylmethyl)-4-piperidinyl]methyl]carbamic acid 1,1-dimethylethyl ester 
• 19867-34-6 N-benzyl-1-oxa-6-azaspiro[2,5]-octane 
• 530-62-1 1,1'-carbonyldiimidazole 
• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 

Downstream Products

• 1538608-34-2 N-(2-amino-5-(4-methylthiophen-2-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1538608-35-3 N-(4-amino-4'-fluoro-[1,1'-biphenyl]-3-yl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1538608-36-4 N-(2-amino-5-(1-methyl-1H-pyrazol-4-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1538608-37-5 N-(2-amino-5-(1-methyl-1H-imidazol-4-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1538608-38-6 N-(2-aminophenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 
• 1607837-16-0 8-(2-amino-3-chloro-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 
• 1607837-47-7 8-(2-amino-5-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-3-(trifluoromethyl)pyridin-4-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one 

Relevant articles and documents

Oxazolidinone compounds and its use in medicine

The invention relates to novel oxazolidinone compounds or stereoisomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically-acceptable salts or prodrugs of the novel oxazolidinone compounds. The invention a

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.

Delayed and prolonged histone hyperacetylation with a selective HDAC1/HDAC2 inhibitor

The identification and in vitro and in vivo characterization of a potent SHI-1:2 are described. Kinetic analysis indicated that biaryl inhibitors exhibit slow binding kinetics in isolated HDAC1 and HDAC2 preparations. Delayed histone hyperacetylation and

Inhibitors of prenyl-protein transferase

The present invention is directed to conformationally constrained compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.